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No curative treatment options are available for advanced hepatocellular carcinoma (HCC). Anti-PD1 antibody therapy can
induce tumor regression in 20% of advanced HCC patients, demonstrating that co-inhibitory immune checkpoint blockade has
therapeutic potential for this type of cancer. However, whether agonistic targeting of co-stimulatory receptors might be able to
stimulate anti-tumor immunity in HCC is as yet unknown. We investigated whether agonistic targeting of the co-stimulatory
receptor GITR could reinvigorate ex vivo functional responses of tumor-inﬁltrating lymphocytes (TIL) freshly isolated from
resected tumors of HCC patients. In addition, we compared GITR expression between TIL and paired samples of leukocytes
isolated from blood and tumor-free liver tissues, and studied the effects of combined GITR and PD1 targeting on ex vivo TIL
responses. In all three tissue compartments, CD4+FoxP3+ regulatory T cells (Treg) showed higher GITR−expression than effector
T-cell subsets. The highest expression of GITR was found on CD4+FoxP3hiCD45RA− activated Treg in tumors. Recombinant GITR-
ligand as well as a humanized agonistic anti-GITR antibody enhanced ex vivo proliferative responses of CD4+ and CD8+ TIL to
tumor antigens presented by mRNA-transfected autologous B-cell blasts, and also reinforced proliferation, IFN-γ secretion and
granzyme B production in stimulations of TIL with CD3/CD28 antibodies. Combining GITR ligation with anti-PD1 antibody
nivolumab further enhanced tumor antigen-speciﬁc responses of TIL in some, but not all, HCC patients, compared to either
single treatment. In conclusion, agonistic targeting of GITR can enhance functionality of HCC TIL, and may therefore be a
promising strategy for single or combinatorial immunotherapy in HCC.
Introduction
Liver cancer is the second most common cause of cancer-
related mortality worldwide, with approximately 750,000 deaths
per year. The most common primary liver cancer is hepatocellular
carcinoma (HCC), an aggressive malignancy derived from
hepatocytes.1,2 Surgical resection and liver transplantation are
curative therapies for patients with early stage disease. However,
about 50% of HCC patients present with advanced disease at
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diagnosis and can only be offered systemic therapies which pro-
vide limited survival advantage.3,4 Therefore, novel therapies for
HCC are urgently needed.
Immune checkpoint antibodies are a new class of cancer
immune therapeutics. T cells are activated upon antigen rec-
ognition via their T-cell receptor and engagement of their co-
stimulatory immune checkpoint receptors with corresponding
ligands on other cells, while they are suppressed upon interac-
tion of their co-inhibitory immune checkpoint receptors with
their ligands. Therapeutic antibodies that block interaction of
the co-inhibitory receptor PD1 with its ligands can unleash
pre-existing anti-cancer T-cell responses within tumors, and
have resulted in recent breakthroughs in clinical treatment of
several types of advanced cancer.5–13 In HCC, a recent trial
showed signiﬁcant tumor load reduction (objective response)
in response to anti-PD1 antibody (nivolumab) therapy in
about 20% of advanced HCC patients, and disease control
with stable disease for ≥6 months in another 17% of
patients.14 Nevertheless, more than 50% of advanced HCC
patients did not respond to nivolumab. Therefore, more effec-
tive immunotherapies and optimal patient selection are still
required for HCC.
Besides blockade of co-inhibitory receptors, agonistic tar-
geting of co-stimulatory receptors has the potential to boost
intra-tumoral T-cell immunity to combat cancer growth and
evoke cancer regression. Importantly, in addition to activating
intra-tumoral T-cell responses, targeting co-stimulatory recep-
tors can stimulate systemic anti-tumor immunity which may
protect against tumor recurrence.15 Currently, antibodies tar-
geting different co-stimulatory receptors are being evaluated
in clinical trials for several types of solid cancer.16,17
One of the co-stimulatory receptors under active clinical inves-
tigation in solid malignancies is CD357, TNF receptor superfamily
member 18 (TNFRSF18), also known as glucocorticoid-induced
TNFR-related protein (GITR). We have previously revealed that
tumor-inﬁltrating T cells in HCC are functionally compromised.
This is due to co-inhibitory interactions,18,19 and to high numbers
of conventional CD4+FoxP3+CD25+ regulatory T cells (Treg)19
and type 1 regulatory T cells20 present in liver tumors, which
inhibit functions of effector T cells. We also demonstrated that
agonistic targeting of GITR can alleviate the suppressive capacity
of liver tumor-derived CD4+CD25+ Treg.21 However, the expres-
sion of GITR on cytotoxic CD8+ tumor-inﬁltrating lymphocytes
(TIL) and CD4+FoxP3− T helper cells (Th) in HCC patients is
unknown. In addition, whether agonistic targeting of GITR can
boost anti-tumor responses of HCC patient-derived TIL has not
been studied, nor is it known whether combining GITR ligation
with PD1 blockade may have synergistic effects on HCC patient-
derived TIL proliferation and activation.
Therefore, in a proof-of-concept preclinical study, we
investigated whether agonistic targeting of the co-stimulatory
receptor GITR could reinvigorate ex vivo functional responses
of TIL from HCC patients. In addition, we compared GITR
expression between TIL and paired samples of leukocytes iso-
lated from peripheral blood and tumor-free liver (TFL) tis-
sues, and studied the effects of combined GITR and PD1
targeting on ex vivo TIL responses.
Patients and Methods
Patients
Thirty-ﬁve patients who were eligible for surgical resection of
HCC and two HCC patients who were eligible for liver trans-
plantation were enrolled in the study from January 2014 to
December 2017. Paired fresh tissue samples from tumors and
surrounding (minimum 1 cm distance from the tumor) tumor-
free liver tissues were obtained, and tumor-inﬁltrating leuko-
cytes and intra-hepatic leukocytes were isolated, respectively.
From part of the patients peripheral blood was collected on the
day of resection. None of the patients received chemotherapy
or immunosuppressive treatment within three months prior to
the surgery. The clinical characteristics of the patients are sum-
marized in Table 1. Eighty percent of the patients included in
the study are from Caucasian origin. The study was approved
What’s new?
Therapeutic antibodies that block interaction of the T cell co-inhibitory receptor PD1 can unleash pre-existing anti-cancer T cell
responses in hepatocellular carcinoma (HCC). However, whether agonistic targeting of co-stimulatory receptors could stimulate
anti-tumor immunity remains unknown. This study is the ﬁrst to show that agonistic targeting of the co-stimulatory receptor
GITR can reinforce the functionality of tumor-inﬁltrating T cells isolated from human tumors. Combined targeting of PD1 and
GITR exerts additive stimulatory effects on ex vivo functionality of tumor-inﬁltrating T cells from HCC patients. Targeting of GITR
thus emerges as a promising strategy for single or combinatorial immunotherapy in HCC.
Table 1. Patient characteristics
HCC (n = 37)
Sex (male/female) 25 / 12
Age (years)1 61.2  3.2
Race (Caucasian/Asian/African) 32 / 2 / 3
Liver fibrosis (metavir score)
F0 / F2 / F3 / F4-cirrhosis
17 / 5 / 3 / 12
AFP (μg/L): <20 /20–400/ >400 26 / 3 / 8
Stage of disease (TNM) St I n = 16, St II n = 16, St IIIa
n = 3, St IVa n = 1, unknown 1
Abbreviations: AFP, alpha fetoprotein; TNM, tumor-node-metastasis.
Etiology of liver disease: no known liver disease (n = 14), HBV/HCV
(n = 4/5), alcohol-related liver disease (n = 4), HBV + alcohol (n = 1),
non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease
(NAFLD) (n = 2/3), HBV + NASH (n = 1), Abernathy (n = 1), hemochroma-
tosis (n = 2).
1Mean  SEM.
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by the local ethics committee, and all the patients signed the
informed consent before tissue and blood donation.
Cell preparation
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll density gradient centrifugation. Single cell suspensions
from tumors and TFL were obtained by tissue digestion.
Brieﬂy, fresh tissues were cut into small pieces and digested
with 0.125 mg/ml collagenase IV (Sigma-Aldrich, St. Louis,
MO) and 0.2 mg/ml of DNAse I (Roche, Indianapolis, IN) in
Hanks’ Balanced Salt solution with Ca2+ and Mg2+ (Sigma,
Zwijndrecht, The Netherlands) for 30–60 min under continu-
ous stirring at 37C. Cell suspensions were ﬁltered through
100 μm pore cell strainers (BD Biosciences, Erembodegem,
Belgium) and mononuclear leukocytes were obtained by Ficoll
density gradient centrifugation. Viability was determined by
trypan blue exclusion.
Flow cytometric analysis
Fresh PBMC and mononuclear leukocytes isolated from
tumors and TFL were analyzed for expression of surface and
intracellular markers using speciﬁc antibodies (Supporting
Information Table 1). Dead cells were excluded using a
LIVE/DEAD ﬁxable dead cell stain kit with aqua ﬂuorescent
reactive dye (Invitrogen, Paisley, UK) or Live/dead stain
eFluor506 (eBioscience, Vienna, Austria). Cell surface staining
with ﬂuorochrome-conjugated antibodies was performed in
the dark at 4C for 30 min, after which cells were ﬁxed and
permeabilized using the FoxP3 staining buffer set
(eBioscience) and stained for intracellular antigens. Cells were
measured by a FACSCanto II or a FACSAria SORP II ﬂow
cytometer (BD Biosciences, San Diego, USA) and analyzed
using FlowJo software version X.0.7 (TreeStar Inc.). Appropri-
ate isotype control antibodies were used for gating purposes.
Ex vivo polyclonal T-cell activation assay
All TIL cultures were performed in RPMI 1640 (Lonza, Breda,
The Netherlands) supplemented with 10% human AB serum
(Sigma), 2 mM L-glutamine (Invitrogen), 50 mM Hepes Buffer
(Lonza), 1% penicillin–streptomycin (Life Technologies), 5 mM
Sodium Pyruvate (Gibco) and 1% minimum essential medium
nonessential amino acids (MEM NEAA) (complete medium) at
37C. TIL were cultured in 96-well round-bottom culture plates
(106 cells/mL) and typically stimulated with anti-human
CD3/CD28 Dynabeads (Gibco-Life Technologies AS, Norway)
at a cell: bead ratio of 10:1. This ratio provides suboptimal
T-cell stimulation.18 To test the effects of GITR stimulation,
1 μg/mL azide-free and low endotoxin soluble GITR ligand
(GITRL, RnD systems) crosslinked with 2.5 μg/mL anti-HA
antibody (RnD systems), or 10 μg/mL humanized IgG1 agonis-
tic antibody against GITR (Pﬁzer Inc.), or the corresponding
isotype control antibody (anti-HA hIgG1 clone 4FNL; Pﬁzer
Inc.) were added. After 4–5 days, culture supernatant was col-
lected and production of IFN-γ and granzyme B was quantiﬁed
by LegendPlex (BioLegend, San Diego, USA). Cells were harvested
and stained with anti-CD8, anti-CD4, and anti-CD3 anti-
bodies (surface staining) and anti-Ki-67 antibody (nuclear
staining). Dead cells were excluded using the LIVE/DEAD ﬁx-
able dead cell stain kit with aqua ﬂuorescent reactive dye, and
T-cell proliferation was determined based on Ki-67 positivity
by ﬂow cytometry analysis.
Ex vivo mRNA-encoded full length tumor antigen-speciﬁc
T-cell stimulation assay
Expansion of patient B cells from PBMC by stimulation with
trimeric CD40 ligand and IL-4, in vitro generation of eGFP, gly-
pican 3 (GPC3) and MAGEC2 mRNA, and mRNA electropora-
tion of B-cell blasts were performed as previously described.18
Tumor-inﬁltrating leukocytes were labeled with 0.1 μM
carboxyﬂuorescein diacetate succinimidyl ester (CFSE, Invitro-
gen), after which 105 TIL in 100 μl complete medium were
transferred to each well of 96-well round-bottom culture
plates. GPC3 mRNA-, MAGEC2 mRNA- or (as a negative
control) eGFP mRNA-transfected autologous CD40-activated
B cells (B cell blasts) in 100 μl of the same medium were
added at a TIL:B-cell ratio of 1:1. TIL were co-cultured with
B-cell blasts in the presence or absence of 1 μg/mL GITRL
crosslinked with 2.5 μg/mL anti-HA antibody, or 10 μg/mL
humanized agonistic antibody against GITR (Pﬁzer Inc.), or
10 μg/mL nivolumab (BMS, obtained from Erasmus MC hos-
pital pharmacy), or corresponding isotype control antibodies
(hIgG1 and anti-BHV hIgG4 clone 26H6 (Pﬁzer Inc.), respec-
tively). After 6 days, supernatants were stored for later cyto-
kine analysis, while cells were harvested, and stained with
CD3, CD4, and CD8 antibodies. Dead cells were excluded
using the LIVE/DEAD ﬁxable dead cell stain kit with aqua
ﬂuorescent reactive dye, and T-cell proliferation was deter-
mined based on CFSE dilution by ﬂow cytometry analysis.
Statistical analysis
All data set distributions were analyzed for normality by the
Shapiro–Wilk normality test. Differences between paired
groups of data were analyzed according to their distribution
by either paired t test or Wilcoxon matched pairs test. The
statistical analysis was performed using GraphPad Prism Soft-
ware (version 5.0). p Values less than 0.05 were considered
statistically signiﬁcant in Figures 3 (except 3C), 4, 5, 7 and
Supporting Information Figure 2 (* = p < 0.05; ** = p < 0.01;
*** = p < 0.001). Bonferroni correction was used to correct
for multiple hypotheses testing, so p values less than
0.025 (0.05 divided by 2) were considered statistically signif-
icant in Figures 1–3c and Supporting Information Figure 1
(* = p < 0.025; ** = p < 0.01; *** = p < 0.001).
Results
CD4+FoxP3+ TIL show high GITR expression
First, we determined frequencies of CD3−CD56+ NK cells,
CD3+CD56+ NKT cells, CD8+ T cells, total CD4+ T cells,
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CD4+FoxP3− T cells, and CD4+FoxP3+ T cells within the
CD45+ cells isolated from blood, TFL tissues, and tumors of
HCC patients. While tumors contained lower frequencies of
NK cells and NKT cells, they contained more T cells within
CD45+ cells than TFL (Supporting Information Fig. 1A). The
distribution of T-cell subsets further showed that CD4+FoxP3+
T cells accumulated within tumors but CD4+FoxP3− T helper
cells not, while proportions of CD8+ T cells in tumors were
reduced compared to TFL (Supporting Information Fig. 1B).
We then analyzed GITR expression within these immune cell
subsets. The proportions of GITR-expressing NK cells
(on average 12% in the tumor), NKT cells (on the average
12% in the tumor), and CD8+ T cells (on average 5% in the
tumor) did not differ among tumor, TFL and blood (Fig. 1a-c).
In contrast, GITR expression was slightly increased on
CD4+FoxP3− T cells in tumor and TFL as compared to blood,
with on average 7% of CD4+FoxP3− cells expressing GITR
(Fig. 1a-c). The highest expression of GITR was observed on
CD4+FoxP3+ TIL (Fig. 1b), with an average of 45% of cells
expressing GITR, which was signiﬁcantly higher than
CD4+FoxP3+GITR+ T-cell proportions in blood and TFL
(Fig. 1a). No signiﬁcant differences in GITR expression on
immune cell subsets in tumors were observed between
patients with ‘no underlying liver disease’, HBV or HCV viral
hepatitis, or other diseases i.e. alcohol-related, NASH, NAFLD
etc., or between patients with no liver ﬁbrosis and patients
with liver ﬁbrosis (metavir score F2-F4) (data not shown).
CD4+FoxP3hiCD45RA− activated Treg are highly abundant in
the tumor and display highest GITR expression
Because functional Treg subsets can be deﬁned by CD45RA
expression,22 we included CD45RA to further deﬁne FoxP3-
expressing CD4+ T-cell populations. The combination of FoxP3
and CD45RA leads to the identiﬁcation of ﬁve CD4+ T-cell sub-
sets: FoxP3loCD45RA+ resting Treg (fraction I), FoxP3hiCD45RA−
activated Treg (fraction II), FoxP3loCD45RA− activated Th
(fraction III), FoxP3−CD45RA− memory Th (fraction IV),
and FoxP3−CD45RA+ naïve Th (fraction V; Fig. 2a).
We evaluated the CD4+FoxP3+ subset distributions in blood,
TFL, and tumor. There was no signiﬁcant difference in the
frequencies of activated Th (fraction III) within CD4+ T cells
among the three compartments (Fig. 2b). Resting Treg (frac-
tion I) were present at low frequencies in blood but rare in
liver tissues, whereas activated Treg (fraction II) were about
nine-fold more abundant in tumors than in TFL or blood
(Fig. 2b).
We then set out to analyze GITR expression on
FoxP3-expressing CD4+ T-cell subsets (fraction I, II, and III).
All fractions expressed GITR, but the highest GITR expression
was found on intra-tumoral activated Treg (fraction II), with
on average nearly 70% of cells expressing GITR (Fig. 2c, d,
and f). Because of the increased proportion of activated Treg
in tumors (Fig. 2b) and the high GITR expression on these
cells (Fig. 2c), we observed an approximate 30-fold increase of
GITR+ activated Treg within CD45+ immune cells in tumors
over TFL and an approximate 50-fold increase of GITR+ acti-
vated Treg within CD45+ immune cells in tumors over blood
(Fig. 2e).
GITR is expressed on activated T-cell subsets
Subsequently, we aimed to identify whether GITR expression
coincided with expression of the activation markers CD25 and
4-1BB (also known as CD137, an accepted marker for detec-
tion of antigen-speciﬁc T-cell responses).23,24 We found that
GITR+ activated Th and activated Treg in liver tissues
expressed signiﬁcantly higher levels of CD25 than their
GITR− counterparts (Fig. 3a). Similarly, GITR+CD4+FoxP3−
Th cells expressed higher levels of CD25 than GITR−CD4+-
FoxP3− Th cells (data not shown).
We further found that on average 60% of activated Treg in
tumors co-expressed GITR and 4-1BB. Proportions of activated
Treg that co-expressed GITR and 4-1BB were signiﬁcantly
higher in tumors than in blood and showed a higher trend in
tumors than in TFL (p = 0.04) (Fig. 3b-c), which was also
observed for CD8+ T cells, CD4+FoxP3− T-cell subsets, and
activated Th (data not shown). GITR-expressing CD8+ T cells,
CD4+FoxP3−CD45RA+ naïve Th, CD4+FoxP3−CD45RA−
memory Th, and activated Th cells in liver tissues and blood
showed a more activated phenotype than their GITR− counter-
parts, whereas GITR+ activated Treg in liver tissues, but not in
blood, showed a more activated phenotype, as marked by
increased 4-1BB expression (Fig. 3d), which is in line with
enhanced CD25 expression on GITR+ T cells.
GITR ligation enhances CD4+ and CD8+ TIL proliferation
We previously showed that engagement of GITR by GITRL
reduced the suppression that HCC tumor-derived Treg exert
on blood-derived CD4+CD25− T cells in ex vivo cultures.19,21
We now evaluated whether GITR ligation can enhance effec-
tor responses of HCC-derived CD4+ and CD8+ TIL. Because
monoclonal antibodies are more amenable to therapeutic
development than recombinant proteins, we also assessed the
effect of a humanized agonistic antibody against GITR
(human IgG1, Pﬁzer Inc.). To test the effect of GITR ligation,
we used two T-cell stimulation assays.
First, we analyzed TIL proliferation and cytokine secretion
after 4- to 5-day culture with anti-CD3/anti-CD28 beads in
the absence or presence of GITRL or anti-GITR agonistic
antibody. GITRL robustly enhanced CD8+ T-cell proliferation
and granzyme B production and slightly enhanced CD4+
T-cell proliferation, whereas anti-GITR antibody signiﬁcantly
enhanced CD8+ T-cell proliferation, granzyme B and IFN-γ
production (Fig. 4). No enhanced proliferation or cytokine
secretion was observed in the presence of the corresponding
hIgG1 isotype control (Fig. 4).
In order to evaluate tumor antigen-speciﬁc responses, we
expanded autologous B-cell blasts from patient PBMC by a 2-
to 3-week culture in the presence of trimeric CD40 ligand and
1114 GITR ligation activates T cells in HCC tumors
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Figure 1. CD4+FoxP3+ TIL from HCC patients show highest GITR expression. (a) GITR+ cell frequencies within NK cells, NKT cells, CD8+,
CD4+FoxP3− and CD4+FoxP3+ T cell subsets in mononuclear leukocytes isolated from blood, tumor-free liver (TFL), and tumor tissues from HCC
patients. (b) As in (a), showing median ﬂuorescence intensities (MFI) of GITR expression on the indicated immune cell subsets. Dots
represent individual patients and lines present means. N = 19–26 patients. ** = p < 0.01; *** = p < 0.001. (c) Representative FACS dot plots
of one patient display the gating strategies.
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IL-4. These B-cell blasts were then transfected with mRNA
encoding the tumor antigens GPC3 or MAGEC2, or eGFP as
a negative control, and co-cultured with CFSE-labeled TIL for
6 days, as previously described.18 Proliferation of CD4+ TIL
and CD8+ TIL in response to GPC3 and/or MAGEC2 was sig-
niﬁcantly enhanced after engagement of GITR by GITRL or
anti-GITR antibody (Fig. 5a-c), in contrast to the correspond-
ing hIgG1 isotype control.
Figure 2. Activated Treg are highly enriched in HCC tumors and express the highest levels of GITR. (a) Representative example of ﬂow cytometric
analysis of CD4+ T cell subsets by FoxP3 and CD45RA, identifying ﬁve fractions: FoxP3loCD45RA+ resting Treg (fraction I), FoxP3hiCD45RA−
activated Treg (fraction II), FoxP3loCD45RA− activated Th (fraction III), FoxP3−CD45RA− memory Th (fraction IV), and FoxP3−CD45RA+ naïve Th
(fraction V). (b) Percentages of fractions I-III within CD4+ T cells. (c) GITR+ frequencies within fractions I-III. (d) Median ﬂuorescence intensities
(MFI) of GITR expression on cells within fractions I-III. (e) Percentages of total activated Treg (left) and GITR+ activated Treg (right) within CD45+
mononuclear leukocytes. Dots represent individual patients and lines present means. N = 12 patients. * = p < 0.025; ** = p < 0.01;
*** = p < 0.001. (f ) Representative FACS histograms of one patient display the expression of GITR in CD4+ T cell subsets.
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Figure 3. GITR expression on activated T cell subsets is accompanied by increased CD25 and 4-1BB expression. (a) GITR+ activated T helper
(CD4+FoxP3loCD45RA−) and activated regulatory T cell (CD4+FoxP3hiCD45RA−) subsets express higher levels of CD25 than their GITR−
counterparts. (b) Representative example of ﬂow cytometric analysis, showing co-expression of GITR and 4-1BB on intra-tumoral activated
Treg (aTreg) (fraction II). (c) Percentages of GITR+4-1BB+ activated Treg in blood, TFL, and tumor. Dots represent individual patients and lines
present means. (d) 4-1BB+ frequencies within GITR− versus GITR+ cells of CD8+ T cells and four different CD4+ T cell subsets in blood, TFL, and
tumor. N = 12 patients. * = p < 0.05; ** = p < 0.01; *** = p < 0.001.
van Beek et al. 1117
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PD1 blockade in combination with GITR ligation further
enhances tumor antigen-speciﬁc responses of TIL from
some patients
Because PD1 blockade with the humanized anti-PD1 antago-
nistic antibody nivolumab resulted in tumor regression (objec-
tive response) in about 20% of patients with advanced HCC,14
we assessed the co-expression of GITR and PD1 on T-cell
subsets and the effects of combined targeting of GITR and
PD1. Within all T-cell subsets the majority of GITR+ cells in
the tumor, TFL and blood co-expressed PD-1. However, PD-1
was expressed on larger proportions of CD8+ T cells,
FoxP3−CD45RA+ naïve Th, FoxP3−CD45RA− memory Th,
activated Th than GITR, and hence only part of PD1+ cells in
these subsets co-expressed GITR. In contrast, the majority of
PD1+ activated Treg in TFL and tumor and of PD1+ resting
Treg in TFL co-expressed GITR (Fig. 6a–b).
Addition of nivolumab signiﬁcantly enhanced ex vivo pro-
liferative responses of CD4+ TIL and almost signiﬁcantly
enhanced CD8+ TIL proliferation to tumor antigens (Fig. 7a-c).
Although the combination of nivolumab with GITRL did not
signiﬁcantly enhance proliferation of tumor antigen-speciﬁc
CD4+ or CD8+ T cells compared to single nivolumab or
GITRL treatment (Supporting Information Fig. 2), individual
patients’ TIL responses (HCC-001, HCC-004, HCC-005,
HCC-006) beneﬁted from the combination of nivolumab and
GITRL (Fig. 7a-c). In addition, we observed that the average
proliferative response to the combination of nivolumab and
GITRL was 19–20% higher in CD4+ T cells and 27–34%
higher in CD8+ T cells, compared to nivolumab alone or
GITRL alone, respectively (Supporting Information Fig. 2).
Discussion
Cancer immunotherapy by targeting GITR has shown anti-
tumor immune responses and tumor regression in a variety of
cancer mouse models, including bladder cancer, colon cancer,
and melanoma.16 Several clinical trials to target GITR by
GITRL or anti-GITR-antibodies in solid tumors are starting,
ongoing, or just completed (a.o. NCT02697591, NCT01239134,
NCT03295942). However, whether GITR targeting can enhance
responsiveness of TIL isolated from human tumors is as yet
unknown. We have previously shown that GITR ligation
decreases the suppressive capacity of conventional Treg present
in HCC tumors.19,21 Based on this observation, we hypothe-
sized that GITR ligation may be able to enhance the respon-
siveness of TIL from HCC patients. In this study, we tested this
hypothesis. We show that GITR ligation indeed enhances
ex vivo TIL proliferation in polyclonal and tumor antigen-
speciﬁc stimulations of TIL isolated from HCC tumors. More-
over, GITRL and anti-GITR antibody enhance effector cytokine
and granzyme B production in TIL cultures (Figs. 4 and 5).
Extending our earlier studies,19,21 in which we showed
enhanced GITR expression on tumor-inﬁltrating Treg com-
pared to their counterparts in TFL and blood in HCC
patients, we now extensively evaluated GITR expression on
different lymphocyte subsets (Figs. 1 and 2). Our data show
Figure 4. GITR ligation enhances ex vivo proliferation and effector molecule production of CD4+ and CD8+ TIL. Effects of soluble GITRL
(1 μg/mL crosslinked with anti-HA antibody) or 10 μg/mL humanized agonistic anti-GITR antibody on proliferation of (a) CD4+ TIL, and (b)
CD8+ TIL upon 4 to 5 days’ culture of tumor-derived mononuclear cells with a suboptimal amount of anti-CD3/CD28 beads. Proliferation was
measured by determination of percentages of CD4+ or CD8+ T cells expressing Ki-67 at the end of the culture. Baseline proliferation (= % of
Ki-67+ T cells in the absence of GITRL or antibodies) was normalized to 100% for each tested patient. Bars show mean percentages of Ki-67+
CD4+ or CD8+ T cells in cultures relative to baseline proliferation in cultures derived from n = 9 patients with SEM. An irrelevant human IgG1
antibody served as an isotype-matched control antibody for the anti-GITR antibody. (c) Production of IFN-γ and d) granzyme B in culture
supernatant was quantiﬁed. Data of patients with detectable amounts of IFN-γ or granzyme B are shown, each line represents one patient.
* = p < 0.05; ** = p < 0.01.
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Figure 5. GITR ligation increases ex vivo proliferation of CD4+ and CD8+ TIL in response to tumor antigens presented by mRNA-transfected
autologous B cells. Effects of soluble GITRL (1 μg/mL crosslinked with anti-HA antibody) or 10 μg/mL humanized agonistic anti-GITR antibody
on proliferation of (a) CD4+ TIL, and (b) CD8+ TIL upon 6 days’ culture of CFSE-labeled tumor-derived mononuclear cells with B cell blasts
electroporated with mRNA encoding tumor antigens GPC3 or MAGEC2 (or eGFP as a negative control). Proliferation was measured by
determination of percentages of CFSElow CD4+ or CD8+ T cells at the end of the culture. Baseline proliferation (= % of CFSElow T cells in the
presence of eGFP-electroporated B cells) was normalized to 100% for each tested patient, and is indicated by a closed green circle. The data
depicted as ‘B cells + TIL’ demonstrate that TIL from all patients showed enhanced responses to MAGEC2 as compared to eGFP, while TIL of
6 patients also responded to GPC3. For those patients whose TIL responded to both tumor antigens, the average response to GPC3- and
MAGEC2-electroporated B cells was depicted. Each line represents one patient. An irrelevant human IgG1 antibody served as an isotype-
matched control antibody for the anti-GITR antibody. Data show responses in TIL cultures of n = 8 patients. * = p < 0.05; ** = p < 0.01
compared to baseline (B cells + TIL). (c) Representative FACS contour plots of one patient display the proliferation of CD4+ and CD8+ TIL in
response to autologous eGFP or MAGEC2-electroporated B cells.
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that intra-tumoral CD4+FoxP3+ T cells, particularly CD4+Fox-
P3hiCD45RA− activated Treg, express the highest levels of
GITR, while CD4+Foxp3− Th cells, CD8+ T cells, NK cells
and NKT cells express lower levels. CD4+FoxP3loCD45RA−
T cells (fraction III), an activated Th subset that is nonsuppres-
sive, produces pro-inﬂammatory cytokines, and can contribute
to anti-tumor immunity,22,25 also expressed lower levels of
GITR compared to activated Treg. GITR+ Treg showed an acti-
vated phenotype, as evidenced by elevated CD25 and 4-1BB
expression (Fig. 3). Together with the high proportions of
CD4+FoxP3hiCD45RA− activated Treg in TIL (Fig. 2b, e), these
data suggest that the preferential target of GITR ligand and
anti-GITR antibody in our TIL cultures were probably highly
activated Treg. However, we do not exclude that targeting of
activated effector T cells which expressed GITR (Fig. 3) con-
tributed to the functional effects of GITRL and anti-GITR anti-
body in our TIL cultures. Indeed, a recent study using an
experimental mouse tumor model showed that anti-GITR anti-
body therapy targets both activated highly suppressive Treg as
well as effector T cells.26
GITRL and anti-GITR antibody resulted in comparable
enhancements of ex vivo TIL proliferation, effector cytokine
and granzyme B production, showing that in our ex vivo cul-
ture conditions a fully humanized anti-GITR antibody is as
effective as the natural trimeric ligand. In vivo targeting
of GITR can boost intra-tumoral T-cell immunity via
several mechanisms: 1) by selective depletion of Treg via
co-engagement of activating Fcγ-receptors on innate immune
cells;26–28 2) by GITR-signaling into Treg, leading to lineage
destabilization and reduction of their suppressive capacity;29 3)
by GITR-signaling into effector T cells, thereby increasing
their resistance to Treg suppression.26,30 Activation of human
GITR-signaling requires trimerization of GITR.16 We used a
trimeric GITR-ligand that we crosslinked using an anti-HA
tag antibody, thereby further increasing its ability to multi-
merize GITR and activate GITR-signaling. Induction of sig-
naling of TNF superfamiliy receptors such as GITR by
agonistic antibodies is thought to require co-engagement of
inhibitory Fcγ-receptors.31,32 Since the anti-GITR antibody
that we used has a human IgG1 Fc part which has a high
binding afﬁnity for all human Fcγ-receptors, including the
inhibitory Fcγ-receptor IIb,33 and we deliberately used unfrac-
tionated TIL which we previously showed to contain innate
immune cells18 that express both activating and inhibitory
Figure 6. Co-expression of GITR and PD1. (a) Representative example of ﬂow cytometric analysis of GITR and PD1 expression on tumor-
derived activated Treg. (b) Mean frequencies of GITR−PD1−, GITR−PD1+, GITR+PD1− and GITR+PD1+ within CD8+ T cells, FoxP3−CD45RA+ Th,
FoxP3−CD45RA− Th, activated Th, resting Treg and activated Treg in blood, TFL, and tumor with SEM. N = 12 patients.
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Figure 7. Combined targeting of GITR and PD1 increases ex vivo proliferation of CD4+ and CD8+ TIL in response to tumor antigens presented
by mRNA-transfected autologous B cells in some patients. Effects of 10 μg/mL antagonistic anti-PD1 antibody (nivolumab) or anti-PD1
antibody combined with soluble GITRL (1 μg/mL crosslinked with anti-HA antibody) on proliferation of (a) CD4+ TIL, and (b) CD8+ TIL upon
6 days’ culture of CFSE-labeled tumor-derived mononuclear cells with B cell blasts electroporated with mRNA encoding tumor antigens GPC3
or MAGEC2 (or eGFP as a negative control). Proliferation was measured by determination of percentages of CFSElow CD4+ or CD8+ T cells at the
end of the culture. Baseline proliferation (= % of CFSElow T cells in the presence of eGFP-electroporated B cells) was normalized to 100% for
each tested patient, and is indicated by a closed green circle. For those patients whose TIL responded to both tumor antigens, the average
response to GPC3- and MAGEC2-electroporated B cells was depicted. Each line represents one patient. An irrelevant human IgG4 antibody
served as an isotype-matched control antibody for the anti-PD1 antibody. Data show responses in cultures of n = 8 patients. * = p < 0.05;
** = p < 0.01 compared to baseline (B cells + TIL). (c) Representative FACS contour plots of one patient display the proliferation of CD4+ and
CD8+ TIL in response to autologous MAGEC2-electroporated B cells.
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Fcγ-receptors (van Beek, unpublished results) to study the
effects of the anti-GITR antibody on TIL responses, we sup-
pose that its effect on TIL responses is also mediated by
induction of GITR-signaling in Treg and effector T cells. The
robust T cell stimulatory activity of the anti-GITR antibody
may be co-determined by its ligand blocking nature, which
prevents reverse signaling of GITR through GITRL to induce
indoleamine 2,3-dioxygenase expression in antigen-presenting
cells and lead to T-cell suppression.34 Whether this anti-GITR
antibody can mediate depletion of Treg in our TIL cultures
remains to be elucidated.
In addition, we evaluated the combination of GITR ligation
and PD1 blockade (Fig. 7 and Supporting Information
Figure 2) because single PD1 blockade with nivolumab shows
clinical efﬁcacy in only a minority of HCC patients.14 In a
mouse ovarian tumor model, the combination of GITR liga-
tion and PD1 blockade induced potent antitumor immunity
and tumor regression, while anti-GITR or anti-PD1 antibodies
alone did not have any therapeutic effect.35 Several clinical
studies in cancer patients are currently studying combinatorial
targeting of GITR and the PD1/PDL1 pathway.17,36 Addition
of nivolumab alone enhanced ex vivo TIL responses to a simi-
lar extent as GITRL (Supporting Information Fig. 2), while
the combination of GITRL and nivolumab further enhanced
tumor antigen-speciﬁc proliferative responses of TIL from
some, but not all patients (Fig. 7). One reason for the limited
additive effect of combined PD-1 and GITR-targeting on TIL
responses may be related to the extensive co-expression of
both target molecules on Treg. About 50% of intra-tumoral
Treg co-expressed GITR and PD-1 (Fig. 6). Importantly,
blockade of PD-L1/PD-1 interaction has been shown to
enhance the suppressive capacity of human Treg,37,38 and
might therefore counteract the reduction of Treg suppressive
function by GITR ligation.
Our data show that about 10% of NK-cells in tumors, TFL
and blood express GITR, although at a lower expression level
than Treg. Accumulating evidence indicates that agonistic
GITR-targeting can suppress human NK cell functions. In
vitro engagement of GITR on human NK cells by GITR-
ligand expressing tumor cells, GITR-ligand-Ig fusion protein,
or soluble GITR-ligand produced by tumor cells or present in
human sera, inhibits their cytotoxic functions and IFN-γ
production.39–41 In addition, targeting of puriﬁed human NK
cells with an agonistic anti-GITR antibody inhibits human
NK-cell proliferation and pro-inﬂammatory cytokine produc-
tion.42 Therefore, whereas our data show that agonistic target-
ing of GITR enhances ex vivo reactivity of tumor-inﬁltrating
T cells of HCC patients, clinical effects of agonistic GITR tar-
geting in cancer patients may be counteracted by suppression
of anti-cancer responses of tumor-inﬁltrating NK cells. The
net clinical effect of GITR-targeting in cancer patients can
only be studied in clinical trials. Whether IFN-γ and gran-
zyme B released into the supernatants of our ex vivo cultures
of human TIL (Fig. 4c-d) were exclusively derived from T cells
or also from NK cells, is uncertain. Therefore, we cannot
exclude that inhibitory effects of GITR-ligation on cytokine
and granzyme B production by NK cells that were present in
the TIL cultures have partially obscured stimulatory effects on
their production by T cells.
Our study has some limitations: 1) since we could often
isolate limited numbers of TIL from patient tumor samples
and the required numbers of TIL in the assays are large, we
could include only a fraction of patients for functional assays;
2) for the same reason, we were not able to investigate the
mechanism of action by which GITRL and anti-GITR anti-
body enhanced ex vivo TIL responses, neither the involvement
of Fcγ-receptor-expressing innate immune cell subsets in the
effects of the anti-GITR antibody; 3) because most of our
patients underwent resection, and a few underwent liver
transplantation, they only represent (very) early stages of
HCC patient population; 4) most patients in our cohort have
no preexisting severe liver ﬁbrosis, in contrast to HCC
patients in many other studies in e.g. Asia.
On the other hand, our study has several strengths: 1) we are
the ﬁrst to show that GITR ligation can enhance responsiveness
of TIL isolated from human tumors; 2) we used total tumor-
inﬁltrating leukocytes to mimic the tumor immune environment
as close as possible; 3) we used an antigen-speciﬁc assay that
included two tumor-associated antigens (GPC3 and MAGEC2)
that are selectively and prevalently expressed in HCC tumors;43
4) we directly compared GITRL with an agonistic anti-GITR
antibody. Since GITR targeting as single treatment or in combi-
nation with targeting of another immune checkpoint was effec-
tive in a variety of cancer models in mice, our data showing
enhanced responses of human HCC TIL upon GITR ligation
may also have relevance for other human cancers.
In sum, our study demonstrates that GITR ligation can
enhance the functionality of tumor-inﬁltrating T cells in
HCC, and therefore may be a promising immunotherapeutic
target for patients with HCC. In addition, our results suggest
that combined targeting of GITR and PD1 may improve anti-
tumor T-cell responses in some, but not all, HCC patients.
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